Handelsbanken Fonder’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$52.4M Sell
910,107
-446,938
-33% -$25.7M 0.15% 109
2026
Q1
$82.3M Buy
1,357,045
+87,125
+7% +$5.08M 0.27% 69
2025
Q4
$68.5M Buy
1,269,920
+140,901
+12% +$6.78M 0.21% 85
2025
Q3
$50.9M Sell
1,129,019
-332,506
-23% -$15.5M 0.16% 119
2025
Q2
$67.7M Sell
1,461,525
-23,002
-2% -$1.13M 0.24% 87
2025
Q1
$90.5M Buy
1,484,527
+6,956
+0.5% +$405K 0.37% 54
2024
Q4
$83.6M Sell
1,477,571
-36,161
-2% -$2.02M 0.32% 58
2024
Q3
$78.3M Buy
1,513,732
+614,701
+68% +$28.8M 0.31% 63
2024
Q2
$37.3M Sell
899,031
-9,204
-1% -$412K 0.16% 128
2024
Q1
$49.3M Sell
908,235
-109,568
-11% -$5.58M 0.21% 104
2023
Q4
$52.2M Buy
1,017,803
+2,400
+0.2% +$126K 0.25% 87
2023
Q3
$58.9M Buy
1,015,403
+35,281
+4% +$2.16M 0.33% 59
2023
Q2
$62.7M Sell
980,122
-43,548
-4% -$2.92M 0.34% 60
2023
Q1
$71M Buy
1,023,670
+41,345
+4% +$2.92M 0.41% 46
2022
Q4
$70.7M Buy
982,325
+4,004
+0.4% +$302K 0.44% 45
2022
Q3
$69.5M Buy
978,321
+198,529
+25% +$14.4M 0.47% 40
2022
Q2
$60M Buy
779,792
+136,074
+21% +$10.4M 0.39% 50
2022
Q1
$47M Sell
643,718
-10,746
-2% -$722K 0.26% 88
2021
Q4
$40.8M Buy
654,464
+38,559
+6% +$2.26M 0.2% 117
2021
Q3
$36.4M Buy
615,905
+5,652
+0.9% +$372K 0.19% 120
2021
Q2
$40.8M Sell
610,253
-43,497
-7% -$2.84M 0.21% 105
2021
Q1
$41.3M Buy
653,750
+6,747
+1% +$420K 0.23% 93
2020
Q4
$40.1M Buy
647,003
+8,390
+1% +$516K 0.24% 97
2020
Q3
$38.5M Buy
638,613
+19,363
+3% +$1.17M 0.28% 79
2020
Q2
$36.4M Buy
+619,250
New +$37M 0.31% 78
2018
Q4
Sell
-51,060
Closed -$3.17M 171
2018
Q3
$3.17M Sell
51,060
-15,000
-23% -$890K 0.06% 157
2018
Q2
$3.66M Sell
66,060
-30,000
-31% -$1.62M 0.07% 157
2018
Q1
$6.08M Sell
96,060
-27,000
-22% -$1.74M 0.12% 140
2017
Q4
$7.54M Buy
123,060
+14,500
+13% +$907K 0.17% 115
2017
Q3
$6.92M Buy
108,560
+23,000
+27% +$1.34M 0.16% 120
2017
Q2
$4.77M Hold
85,560
0.12% 136
2017
Q1
$4.65M Sell
85,560
-30,000
-26% -$1.65M 0.13% 123
2016
Q4
$6.75M Sell
115,560
-25,000
-18% -$1.37M 0.21% 103
2016
Q3
$7.58M Sell
140,560
-805
-0.6% -$51.7K 0.22% 109
2016
Q2
$10.4M Buy
141,365
+23,000
+19% +$1.63M 0.43% 75
2016
Q1
$7.56M Sell
118,365
-210,689
-64% -$13.3M 0.32% 84
2015
Q4
$22.6M Buy
+329,054
New +$21.7M 0.44% 70

Other funds holding BMY

Handelsbanken Fonder's BMY Position: Q2 2026 in Review

Handelsbanken Fonder reduced its Bristol-Myers Squibb (BMY) stake by 33% in Q2 2026, selling an estimated $25.7M and leaving 910,107 shares worth $52.4M. The position accounts for 0.15% of the portfolio, ranked #109.

Handelsbanken Fonder first reported a position in BMY in Q4 2015 and has held it in 37 quarters since. The position peaked at $90.5M in Q1 2025. 1,297 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

  • Handelsbanken Fonder held 910,107 shares of Bristol-Myers Squibb worth $52.4M as of Q2 2026.
  • Handelsbanken Fonder sold 446,938 Bristol-Myers Squibb shares in Q2 2026, an estimated $25.7M.
  • Bristol-Myers Squibb made up 0.15% of Handelsbanken Fonder's portfolio in Q2 2026, its #109 holding.
  • Handelsbanken Fonder first reported a position in Bristol-Myers Squibb in Q4 2015 and has held it in 37 quarters since.
  • Handelsbanken Fonder's Bristol-Myers Squibb position peaked at $90.5M in Q1 2025.
  • 1,297 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Handelsbanken Fonder's 13F filing for Q2 2026, filed 10 Jul 2026.